Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug for weight management. The Food and Drug Administration’s approval ...

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...

There's no doubt that Roche is playing catchup in the category, one of a lengthening list of pharma companies ... a once-daily formulation of its oral GLP-1 drug danuglipron as its preferred ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

On the flip side, recent studies show that GLP-1 medications may decrease a person’s risk for cardiovascular disease and dementia. Now, a new study recently published in the journal Nature ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...